Skip to main content

Table 7 Summary statistics for the clinician efficacy scores assessed more than 24 hours after surgery

From: Robenacoxib versus meloxicam for the control of peri-operative pain and inflammation associated with orthopaedic surgery in cats: a randomised clinical trial

Response Visits Robenacoxib (s.c. + oral) Meloxicam s.c. + oral placebo P value (Mann–Whitney test) Quotient robenacoxib:meloxicam (RMANCOVA) P value (RMANCOVA) Transformation for RMANCOVA analysis
   Mean (SD) Mean (SD)   Mean 95% CI   Exponential P value for normality (Shapiro-Wilks test)
Global investigator score (primary end point) V5 1.86 (1.61) 1.98 (1.91) 0.93 0.968 0.682–1.316 0.84 0 (log) 0.53
Posture V5 0.70 (0.68) 0.78 (0.74) 0.72 1.007 0.527–1.693 0.98 −1 (reciprocal) <0.0001
Behaviour V5 0.42 (0.59) 0.54 (0.84) 1.0 1.064 0.565–1.786 0.82 −0.5 (reciprocal of square root) <0.0001
Pain on palpation/manipulation V5 & VF 0.44 (0.62) 0.52 (0.84) 0.65 1.032 0.768–1.343 0.82 0.5 (square root) <0.0001
Overall pain control V5 & VF 0.76 (0.62) 0.76 (0.71) 0.49 1.143 0.807–1.567 0.42 0.5 (square root) <0.0001
Inflammation intensity VF 0.15 (0.04) 0.25 (0.06) 0.16 1.642 0.752–3.695 0.18 0 (log) <0.0001
  1. CI: confidence interval; s.c.: subcutaneous; VF: final visit.
  2. Values are mean (SD) for each group and quotient values with 95% CI for the ratio robenacoxib/meloxicam. Data are from assessments at V5 and VF.
  3. Non-inferiority of robenacoxib versus meloxicam was concluded if the lower limit of the 95% CI was >0.75 (shown in bold). P values <0.05 are also shown in bold.
  4. The global investigator score (the primary end point) ranged from 0 to 9. All other end points (secondary end points) ranged from 0 to 3.